News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademySponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
CNS Drug Development Resources|
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos
Advertisement

Lars Behrend, PhD

Advertisement

Articles by Lars Behrend, PhD

Consequences of Brexit for Clinical Trials in Europe

ByLars Behrend, PhD,Ana Cosme, PhD,Michael Sigmund
October 14th 2021

Higher costs headline list of new challenges faced by CROs and sponsors.

Advertisement

Latest Updated Articles

  • Consequences of Brexit for Clinical Trials in Europe
    Consequences of Brexit for Clinical Trials in Europe

    Published: October 14th 2021 | Updated:



Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

Evolving Trial Designs Advance Precision Medicine Through Basket, Umbrella, and Platform Models

2

ACT Brief: AI, Caplyta Approval, and FDA Priority Vouchers

3

Scaling Recruitment Across Therapeutic Areas and Regions

4

Bezuclastinib Plus Sunitinib Achieves Strong PFS Benefit in Phase III PEAK Trial for Imatinib-Resistant GIST

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us